

Market Announcement

10 February 2025

Arovella Therapeutics Limited (ASX: ALA) – Suspension from Quotation

Description

The securities of Arovella Therapeutics Limited ('ALA') will be suspended from quotation immediately under Listing Rule 17.2, at the request of ALA, pending the release of an announcement regarding a capital raising.

Issued by

ASX Compliance

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250



10 February 2025

Melissa Kostopoulos
Adviser, Listings Compliance (Melbourne)
ASX Compliance Pty Ltd
Level 4, Rialto North Tower
525 Collins Street
Melbourne VIC 3000

BY EMAIL to: melissa.kostopoulos@asx.com.au

Dear Melissa

REQUEST FOR VOLUNTARY SUSPENSION

Arovella Therapeutics Limited (ASX: ALA) (the Company) requests voluntary suspension of the Company's quoted securities on the Australian Securities Exchange (ASX) in accordance with ASX Listing Rule 17.2, effective from commencement of trading today, 10 February 2025.

In accordance with Listing Rule 17.2, the Company provides the following information in relation to the request:

1. Voluntary suspension is necessary to assist the Company in managing its continuous disclosure obligations, as the Company expects to make a material update announcement to the market in connection with the capital raising placement announced on 10 January 2025.
2. The Company requests that the voluntary suspension remain in place until the earlier of commencement of normal trading on 17 February 2025 or when the announcement is released to the market. The Company expects to make the announcement to the market before the commencement of normal trading on 17 February 2025.
3. The Company is not aware of any reason why the voluntary suspension should not be granted or of any further information necessary to inform the market about the voluntary suspension.

Please contact me if you require any further information concerning this matter.

This request has been authorised by the Board of Arovella Therapeutics Limited.

Kind regards

A handwritten signature in black ink, appearing to be 'Tim Luscombe', written over a horizontal line.

Tim Luscombe
Company Secretary & CFO
Arovella Therapeutics Limited